CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; new cold fill manufacturing service to the pharmaceutical industry, and LEAPS technology, with two products: H1N1, a swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted. It is the cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer.
Research Alerts:
Receive alerts on the latest reports on Cel-Sci Corporation
Subscribe to Research Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
